Kindred Biosciences, Inc.
If you purchased Kindred Biosciences, Inc. securities and would like to join the action, please click "Join This Action" below.
KINDRED BIOSCIENCES MERGER INVESTIGATION: HALPER SADEH LLP ANNOUNCES INVESTIGATION INTO WHETHER THE SALE OF KINDRED BIOSCIENCES, INC. IS FAIR TO SHAREHOLDERS; INVESTORS ARE ENCOURAGED TO CONTACT THE FIRM – KIN
June 16, 2021.
New York, New York—Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Kindred Biosciences, Inc. (NASDAQ: KIN) to Elanco Animal Health Incorporated for $9.25 per share is fair to Kindred Biosciences shareholders.
The investigation concerns whether Kindred Biosciences and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for Kindred Biosciences shareholders; (2) determine whether Elanco is underpaying for Kindred Biosciences; and (3) disclose all material information necessary for Kindred Biosciences shareholders to adequately assess and value the merger consideration. On behalf of Kindred Biosciences shareholders, Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.